Table 2.
Medication use
| Factor |
Overall (n = 1183) |
Fibrosis 0-2 (n = 802) |
Fibrosis 3-4 (n = 381) |
P value | |||
| n | Statistics | n | Statistics | n | Statistics | ||
| Oral hypoglycemic medications | 1183 | 691 (58.4) | 802 | 494 (61.6) | 381 | 197 (51.7) | 0.0012 |
| Oral hypoglycemic duration (mo) | 691 | 19.4 (5.0, 52.1) | 494 | 20.6 (5.5, 54.4) | 197 | 17.4 (3.4, 50.0) | 0.0981 |
| Metformin use | 1183 | 631 (53.3) | 802 | 461 (57.5) | 381 | 170 (44.6) | < 0.0012 |
| Metformin duration (mo) | 631 | 20.0 (5.1, 53.3) | 461 | 20.8 (5.4, 54.5) | 170 | 18.3 (4.5, 52.1) | 0.361 |
| Glipizide use | 1183 | 116 (9.8) | 802 | 82 (10.2) | 381 | 34 (8.9) | 0.482 |
| Glipizide duration (mo) | 116 | 17.2 (5.6, 45.4) | 82 | 19.2 (5.5, 47.7) | 34 | 16.4 (6.0, 42.2) | 0.851 |
| Pioglitazone use | 1183 | 136 (11.5) | 802 | 100 (12.5) | 381 | 36 (9.4) | 0.132 |
| Pioglitazone duration (mo) | 136 | 15.5 (5.6, 44.8) | 100 | 15.8 (6.1, 51.9) | 36 | 12.5 (3.0, 40.8) | 0.301 |
| Sitagliptin/Januvia use | 1183 | 147 (12.4) | 802 | 100 (12.5) | 381 | 47 (12.3) | 0.952 |
| Sitagliptin/Januvia duration (mo) | 147 | 7.2 (1.6, 26.2) | 100 | 7.4 (2.3, 26.6) | 47 | 5.0 (0.30, 24.9) | 0.231 |
| Saxagliptin use | 1183 | 10 (0.85) | 802 | 9 (1.1) | 381 | 1 (0.26) | 0.132 |
| Insulin | 1183 | 370 (31.3) | 802 | 253 (31.5) | 381 | 117 (30.7) | 0.772 |
| Insulin duration (mo) | 370 | 10.9 (2.7, 34.0) | 253 | 11.9 (3.0, 36.8) | 117 | 8.3 (2.5, 25.3) | 0.121 |
| Liraglutide use | 1183 | 69 (5.8) | 802 | 61 (7.6) | 381 | 8 (2.1) | < 0.0012 |
| Liraglutide duration (mo) | 69 | 8.9 (2.6, 21.2) | 61 | 8.6 (2.5, 17.9) | 8 | 20.8 (5.0, 35.0) | 0.131 |
| Detemir/Levemir use | 1183 | 67 (5.7) | 802 | 48 (6.0) | 381 | 19 (5.0) | 0.492 |
| Detemir/Levemir duration (mo) | 67 | 5.9 (1.1, 17.7) | 48 | 3.9 (0.85, 16.4) | 19 | 9.0 (1.8, 17.7) | 0.391 |
| Lantus use | 1183 | 202 (17.1) | 802 | 127 (15.8) | 381 | 75 (19.7) | 0.102 |
| Lantus duration (mo) | 202 | 8.2 (0.80, 37.6) | 127 | 9.2 (0.90, 42.8) | 75 | 6.6 (0.20, 25.1) | 0.171 |
| Humulin use | 1183 | 65 (5.5) | 802 | 49 (6.1) | 381 | 16 (4.2) | 0.182 |
| Humulin duration (mo) | 65 | 12.0 (2.8, 34.0) | 49 | 12.8 (2.0, 34.9) | 16 | 8.4 (5.2, 18.7) | 0.881 |
| Byetta use | 1183 | 119 (10.1) | 802 | 83 (10.3) | 381 | 36 (9.4) | 0.632 |
| Byetta duration (mo) | 119 | 10.2 (3.8, 24.0) | 83 | 11.9 (4.4, 24.0) | 36 | 7.1 (2.5, 24.5) | 0.211 |
| Antihypertensive medications | 1183 | 787 (66.5) | 802 | 538 (67.1) | 381 | 249 (65.4) | 0.562 |
| Antihypertensive duration (mo) | 787 | 26.8 (4.7, 63.1) | 538 | 31.3 (5.8, 65.8) | 249 | 18.1 (3.1, 55.5) | 0.0101 |
| Lisinopril use | 1183 | 377 (31.9) | 802 | 274 (34.2) | 381 | 103 (27.0) | 0.0142 |
| Lisinopril duration (mo) | 377 | 16.1 (3.8, 49.0) | 274 | 18.1 (3.6, 49.4) | 103 | 12.4 (5.2, 48.6) | 0.861 |
| Losartan use | 1183 | 112 (9.5) | 802 | 71 (8.9) | 381 | 41 (10.8) | 0.292 |
| Losartan duration (mo) | 112 | 18.6 (3.2, 51.4) | 71 | 24.1 (6.2, 54.3) | 41 | 9.1 (2.1, 25.8) | 0.0771 |
| Furosemide use | 1183 | 252 (21.3) | 802 | 135 (16.8) | 381 | 117 (30.7) | < 0.0012 |
| Furosemide duration (mo) | 252 | 8.7 (1.8, 39.4) | 135 | 10.9 (2.3, 47.2) | 117 | 7.9 (1.4, 30.0) | 0.161 |
| Hydrochlorothiazide use | 1183 | 371 (31.4) | 802 | 279 (34.8) | 381 | 92 (24.1) | < 0.0012 |
| Hydrochlorothiazide duration (mo) | 371 | 32.9 (7.9, 65.6) | 279 | 34.4 (9.2, 67.1) | 92 | 22.6 (4.8, 58.0) | 0.0891 |
| Spironolactone use | 1183 | 115 (9.7) | 802 | 47 (5.9) | 381 | 68 (17.8) | < 0.0012 |
| Spironolactone duration (mo) | 115 | 5.4 (0.90, 29.1) | 47 | 18.7 (3.6, 46.9) | 68 | 3.0 (0.25, 10.4) | < 0.0012 |
| Amlodipine use | 1183 | 180 (15.2) | 802 | 128 (16.0) | 381 | 52 (13.6) | 0.302 |
| Amlodipine duration (mo) | 180 | 14.1 (3.0, 40.4) | 128 | 14.7 (3.0, 40.9) | 52 | 12.2 (3.5, 31.2) | 0.451 |
| Metoprolol use | 1183 | 273 (23.1) | 802 | 185 (23.1) | 381 | 88 (23.1) | 0.992 |
| Metoprolol duration (mo) | 273 | 11.4 (0.20, 45.1) | 185 | 12.2 (0.20, 45.9) | 88 | 10.0 (0.20, 36.1) | 0.411 |
| Carvedilol use | 1183 | 50 (4.2) | 802 | 28 (3.5) | 381 | 22 (5.8) | 0.0682 |
| Carvedilol duration (mo) | 50 | 8.9 (2.3, 22.3) | 28 | 11.3 (1.4, 28.7) | 22 | 8.4 (2.9, 13.5) | 0.391 |
| Antilipidemic medications | 1183 | 522 (44.1) | 802 | 380 (47.4) | 381 | 142 (37.3) | 0.0012 |
| Antilipidemic duration (mo) | 522 | 24.3 (5.3, 54.6) | 380 | 24.8 (5.5, 62.4) | 142 | 20.9 (4.4, 43.3) | 0.0861 |
| Rosuvastatin use | 1183 | 84 (7.1) | 802 | 61 (7.6) | 381 | 23 (6.0) | 0.332 |
| Rosuvastatin duration (mo) | 84 | 10.4 (2.7, 40.8) | 61 | 10.8 (3.0, 35.4) | 23 | 7.7 (2.2, 41.2) | 0.581 |
| Atorvastatin use | 1183 | 243 (20.5) | 802 | 179 (22.3) | 381 | 64 (16.8) | 0.0282 |
| Atorvastatin duration (mo) | 243 | 21.0 (5.3, 61.9) | 179 | 23.5 (5.4, 66.7) | 64 | 14.6 (4.4, 45.4) | 0.301 |
| Simvastatin use | 1183 | 251 (21.2) | 802 | 187 (23.3) | 381 | 64 (16.8) | 0.0102 |
| Simvastatin duration (mo) | 251 | 15.6 (3.4, 45.8) | 187 | 15.6 (3.6, 51.1) | 64 | 16.5 (1.6, 36.8) | 0.211 |
| Pravastatin use | 1183 | 79 (6.7) | 802 | 57 (7.1) | 381 | 22 (5.8) | 0.392 |
| Pravastatin duration (mo) | 79 | 13.8 (2.4, 33.9) | 57 | 13.8 (2.0, 30.7) | 22 | 15.4 (4.3, 34.7) | 0.811 |
| Gemfibrozil use | 1183 | 38 (3.2) | 802 | 27 (3.4) | 381 | 11 (2.9) | 0.662 |
| Gemfibrozil duration (mo) | 38 | 12.3 (3.0, 50.5) | 27 | 7.9 (2.1, 49.0) | 11 | 33.5 (5.8, 62.3) | 0.121 |
| Fenofibrate use | 1183 | 109 (9.2) | 802 | 78 (9.7) | 381 | 31 (8.1) | 0.382 |
| Fenofibrate duration (mo) | 109 | 17.2 (5.7, 40.7) | 78 | 22.0 (6.0, 44.6) | 31 | 12.6 (3.1, 28.7) | 0.271 |
| Aspirin use | 1183 | 339 (28.7) | 802 | 245 (30.5) | 381 | 94 (24.7) | 0.0372 |
| Aspirin dose | 335 | 241 | 94 | 0.982 | |||
| 81 mg | 328 (97.9) | 236 (97.9) | 92 (97.9) | ||||
| 325 mg | 7 (2.1) | 5 (2.1) | 2 (2.1) | ||||
1
Kruskal-Wallis test.
2
Pearson's χ2 test. Statistics presented as median (P25, P75) or n (%).